167 followers
RT @OhioHealthMS: High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study https://t.co/SWDYzPN48Y
RT @OhioHealthMS: High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study https://t.co/SWDYzPN48Y
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study https://t.co/SWDYzPN48Y